Repeat Antibody Testing May Be Unnecessary for Some Patients With SLE
Testing for anti-ENA should not be repeated routinely in patients with systemic lupus erythematosus following at least 1 negative result.
Results from a phase 2 study suggest that ustekinumab might be an effective therapy in systemic lupus erythematosus.
Therapeutic drug monitoring may be useful to help clinicians assess nonadherence in patients with SLE.
Patients with systemic lupus erythematosus have a high risk for postoperative complications and mortality following major surgery compared with patients without SLE.